Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Identification of virus-specific B-cell epitopes by convalescent plasma from COVID-19 patients

Ling Wang\textsuperscript{a,b,*}, Juan Zhao\textsuperscript{a,b}, Madison Schank\textsuperscript{a,b}, Sushant Khanal\textsuperscript{a,b}, Xindi Dang\textsuperscript{a,b}, Dechao Cao\textsuperscript{a,b}, Lam N.T. Nguyen\textsuperscript{a,b,}\textsuperscript{*}, Yi Zhang\textsuperscript{a}, Xiao Y. Wu\textsuperscript{a,*}, James L. Adkins\textsuperscript{a,*}, Justin Brueggeman\textsuperscript{a,*}, Jinyu Zhang\textsuperscript{a,b}, Shunbin Ning\textsuperscript{a,b,}, Mohamed El Gazzar\textsuperscript{a,b,}, Jonathan P. Moorman\textsuperscript{a,b,c,*}, Zhi Q. Yao\textsuperscript{a,b,c,*}

\textsuperscript{a} Center of Excellence for Inflammation, Infectious Disease and Immunity, James H. Quillen College of Medicine, East Tennessee State University, Johnson City, TN 37614, USA
\textsuperscript{b} Division of Infectious, Inflammatory and Immunologic Diseases, Department of Internal Medicine, Quillen College of Medicine, ETSU, Johnson City, TN 37614, USA
\textsuperscript{c} Hepatitis (HCV/HBV/HIV) Program, James H. Quillen VA Medical Center, Department of Veterans Affairs, Johnson City, TN 37614, USA

\textbf{A R T I C L E I N F O}

Keywords:
B-cell epitopes
COVID-19
Convalescent plasma
Neutralizing antibodies
SARS-CoV-2

\textbf{A B S T R A C T}

Identification of immunologic epitopes against SARS-CoV-2 is crucial for the discovery of diagnostic, therapeutic, and preventive targets. In this study, we used a pan-coronavirus peptide microarray to screen for potential B-cell epitopes and validated the results with peptide-based ELISA. Specifically, we identified three linear B-cell epitopes on the SARS-CoV-2 proteome, which were recognized by convalescent plasma from COVID-19 patients. Interestingly, two epitopes (S 809–823 and R1ab 909–923) strongly reacted to convalescent plasma collected at the early phase (< 90 days) of COVID-19 symptom onset, whereas one epitope (M 5–19) reacted to convalescent plasma collected > 90 days after COVID-19 symptom onset. Neutralization assays using antibody depletion with the identified spike (S) peptides revealed that three S epitopes (S 557–571, S 789–803, and S 809–823) elicited neutralizing antibodies in COVID-19 patients. However, the levels of virus-specific antibody targeting S 789–803 only positively correlated with the neutralizing rates at the early phase (<60 days) after disease onset, and the antibody titers diminished quickly with no correlation to the neutralizing activity beyond two months after recovery from COVID-19. Importantly, stimulation of peripheral blood mononuclear cells from COVID-19-recovered patients with these SARS-CoV-2 S peptides resulted in poor virus-specific B cell activation, proliferation, differentiation into memory B cells, and production of immunoglobulin G (IgG) antibodies, despite the B-cells being functionally competent as demonstrated by their response to non-specific stimulation. Taken together, these findings indicate that these newly identified SARS-CoV-2-specific B-cell epitopes can elicit neutralizing antibodies, with titers and/or neutralizing activities declining significantly within 2–3 months in the convalescent plasma of COVID-19 patients.

\textbf{1. Introduction}

Historically, human coronavirus (HCoV) infections have led to global pandemics every decade, including severe acute respiratory syndrome (SARS) in 2003, Middle East respiratory syndrome (MERS) in 2010, and the most recent novel coronavirus infectious disease-2019 (COVID-19, caused by SARS-CoV-2) in late 2019. To date, there are nearly 253 million confirmed cases of COVID-19 worldwide, with more than 5 million deaths recorded by WHO (Organization, 2021). In the United States, more than 46.6 million people have been infected with SARS-CoV-2, resulting in 755,950 deaths, surpassing the approximately 675,000 deaths that occurred in the 1918 Spanish flu pandemic (Johnson and Mueller, 2002). Therefore, a better understanding of the host immune responses to SARS-CoV-2 is critical for combating future HCoV pandemics.

Immunological memory is an essential aspect of the host immune system, as it can respond rapidly and effectively to previously encountered immunogenic epitopes of different pathogens (Janeway et al.,...
There is an urgent need to identify SARS-CoV-2-specific epitopes and to determine if COVID-19-recovered patients can develop sustained antibody and functional MTC/MBC responses that protect against subsequent SARS-CoV-2 infections. Thus far, data on SARS-CoV-2 immunodominant epitopes remain mostly limited to bioinformatic predictions of human T- and B-cell epitopes using computerized tools (Griffoni et al., 2020; Zheng and Song, 2020; Ahmed et al., 2020). In addition, limited studies (Wang et al., 2020; Pohl et al., 2020) have analyzed virus-specific epitopes in COVID-19 patients using proteome microarrays, which need to be further validated. We have recently reported that COVID-19 convalescent plasma can block SARS-CoV-2 as well as SARS-CoV spike (S) protein-mediated cell-cell fusion and virus entry (Wang et al., 2021). Moreover, we identified SARS-CoV-2 MTC epitopes through microarray screening and ELISpot using peripheral blood mononuclear cells (PBMCs) from COVID-19-recovered subjects (Zhao et al., 2021).

In the present study, we further identified and characterized SARS-CoV-2-specific B cell epitopes using COVID-19 convalescent plasma. We found that, despite the occurrence of antibodies against these epitopes in the plasma of COVID-19-recovered patients, these antibodies were not long-lasting, lost their neutralizing titers and/or activities within 2-3 months after recovery from the infection. These findings support the notion that the COVID-19 vaccine boosters may be necessary to provide extended protection from re-infection and developing severe symptoms in SARS-CoV-2-recovered patients and COVID-19-vaccinated individuals.

2. Materials and methods

2.1. Study subjects

The study protocol was approved by the joint Institutional Review Board (IRB) of East Tennessee State University and James H. Quillen VA Medical Center (ETSU/VA IRB# 0519.24 s). Written informed consent was obtained from all participants. The study was comprised two populations: 76 COVID-19-recovered subjects and 44 control subjects, which included 35 healthy subjects (HS), 4 Influenza patients, 1 HIV patient, and 4 HCV patients. All control subjects were all confirmed healthy individuals.

2.2. Peptide microarrays

To map the dominant linear B-cell epitopes recognized in COVID-19 patients, RepiTope Antigen Collection Pan-Coronavirus Peptide Microarrays (Product code: RT-HD-CoV2) were performed by JPT Peptide technologies (Berlin, Germany), using unheated fresh plasma from six COVID-19 patients (S19, S23, S25, S26, S28, and S30) and own HS. The plasma was diluted (1:200) with T20 buffer and incubated for 2 h at 30 °C on a microarray slide using the TECAN HS4-00 microarray processing station. Following sample incubation, a secondary, fluorescently labeled antibody specific to human IgG was added at a concentration of 0.1 µg/ml and incubated for 45 min. After washing and drying, the slides were scanned with a high-resolution laser scanner at 635 nm to obtain fluorescence intensity profiles. To enhance weak interactions, the slides were scanned with a receiver gain of 650 V. Finally, images were acquired and quantified to yield a mean pixel value for each peptide.

Control incubation with the secondary antibody only (no plasma) was performed in parallel to assess non-specific binding to the peptides and to determine assay performance.

2.3. Peptide-based enzyme-linked immunosorbent assay (Peptide-ELISA)

A total of 13 peptides (Table 1) - that were recognized more often by plasma from COVID-19 patients than HS control - were synthesized by GenScript (Piscataway, NJ) to verify and validate the peptide-antibody interactions using Peptide-ELISA. Next, Invitrogen Nunc Maxisorp flat-bottom 96-well ELISA plates (Waltham, MA) were coated with 5 µg/ml of these synthetic peptides in 50 mM carbonate-bicarbonate buffer (Bioworld, Dublin, OH) by incubating overnight at 4 °C. The plates were washed three times with PBS buffer containing 0.05 % Tween 20 (PBSTw, 250 µl/well), and then blocked with 3 % BSA/PBSTw for 1 h at 37 °C. Plasma from 66 COVID-19-recovered subjects and 26 control subjects (21 HS, 1 HIV, and 4 HCV patients) was diluted (1:100) and incubated with the peptide-coated plates for 1 h at 37 °C. After washing three times, the plates were incubated with diluted (1:4000) horseradish peroxidase (HRP)-conjugated mouse anti-human IgG antibody (Fisher, Pittsburgh, PA) for 1 h at 37 °C, followed by washing. The plates were developed using ABTS (ThermoFisher, Waltham, MA) and read at 410 nm with a BioTek SYNERGY H1 microplate reader.

2.4. Detection of SARS-CoV-2 NAbs

To assess neutralizing antibodies (NAbs) in COVID-19 patients’ plasma that inhibited SARS-CoV-2 S RBD-ACE2 interactions, the SARS-CoV-2 Surrogate Virus Neutralization Test kit was used per the manufacturer’s protocol (GenScript). A neutralizing antibody against SARS-CoV-2 S protein was used as a positive control. First, the diluted (1:10) positive and negative controls and patient plasma were, respectively, pre-incubated with HRP conjugated RBD, to allow the NAbs in the positive control and patient plasma to conjugate with HRP-RBD, and then the mixture was added to a 96-well plate pre-coated with human ACE2 protein (hACE2). After washing and incubating with TMB solution, stop solution was added and the absorbance was read at 450 nm using a BioTek SYNERGY H1 microplate reader. The NAb levels were calculated based on their inhibition extents according to the following equation: [(1-OD value of samples/OD value of negative control) × 100 %].

2.5. Peptide affinity depletion of COVID-19 patient plasma

Invitrogen Nunc Maxisorp flat-bottom 96-well ELISA plates were pre-coated with 5 µg/ml of BSA (control), SARS-CoV-2 S protein were recognized more often by plasma from COVID-19 patients than HS control - were synthesized by GenScript (Piscataway, NJ) to verify and validate the peptide-antibody interactions using Peptide-ELISA. Next, Invitrogen Nunc Maxisorp flat-bottom 96-well ELISA plates (Waltham, MA) were coated with 5 µg/ml of these synthetic peptides in 50 mM carbonate-bicarbonate buffer (Bioworld, Dublin, OH) by incubating overnight at 4 °C. The plates were washed three times with PBS buffer containing 0.05 % Tween 20 (PBSTw, 250 µl/well), and then blocked with 3 % BSA/PBSTw for 1 h at 37 °C. Plasma from 66 COVID-19-recovered subjects and 26 control subjects (21 HS, 1 HIV, and 4 HCV patients) was diluted (1:100) and incubated with the peptide-coated plates for 1 h at 37 °C. After washing three times, the plates were incubated with diluted (1:4000) horseradish peroxidase (HRP)-conjugated mouse anti-human IgG antibody (Fisher, Pittsburgh, PA) for 1 h at 37 °C, followed by washing. The plates were developed using ABTS (ThermoFisher, Waltham, MA) and read at 410 nm with a BioTek SYNERGY H1 microplate reader.
2.6. Pseudovirus neutralization assay

SARS-CoV-2-Δ19 Pseudotyped Luciferase-EGFP lentivirus was produced as described previously (Wang et al., 2021). The 293T/ACE2 target cells were seeded in a 96-well plate (10^4 cells in 100 µl medium per well) and cultured overnight in a 5 % CO₂ incubator at 37 °C. The depleted patient plasma was mixed with the pseudovirus. Each 100 µl of the mixture contained 30 µl depleted plasma, 40 µl pseudovirus, 15 µl DMEM, 5 µl Fetal Bovine Serum (FBS), 1 % Gibco Penicillin-Streptomycin, and 5 µg/ml polybrene (ThermoFisher). After incubating for 1 h at 37 °C, the mixture was added to the cultured 293T/ACE2 cells. The fluorescent images were captured at 72 h post-infection with an EVOS FL Image System (ThermoFisher). The infected 293T/ACE2 cells were lysed and the luciferase activities were measured using the Nano-Glo Luciferase Assay System (Promega, Madison, WI) and a BioTek SYNERGY H1 microplate reader.

2.7. B cell activation by SARS-CoV-2 peptides

PBMCs from 8 COVID-19-recovered subjects (collected > 90 days post-infection) and 8 healthy subjects were seeded in 24-well plates (3 × 10^5 cells/well), and stimulated without or with 5 µg/ml SARS-CoV-2 S protein, mixed peptides S 557–571, S 789–803 and S 809–823 (1.67 µg/ml each), or 1 µg/ml R848 plus 10 ng/ml IL-2 for 72 h. To measure the expression levels of the following cell surface markers, the cells were harvested and stained with anti-human CD19-FITC, anti-human CD86-PE, anti-human PDL1-APC antibodies (Biolegend); or stained with anti-human CD19-FITC, anti-human CD27-BV421 (Biolegend), anti-human CD20-PerCP-Cy5.5, anti-human CD38-AF700, anti-human IgD-PE-Cy7, anti-human IgG-PE, anti-human IgM-APC (BD Biosciences), and anti-human CD21-SB600 (ThermoFisher) antibodies at RT for 20 min. To measure Ki67 and T-bet expression levels, the cells were pre-stained with anti-human CD19-FITC, anti-human CD20-PerCP-Cy5.5, anti-human CD38-AF700, anti-human CD21-SB600, and anti-human CD27-BV421, or anti-human IgD-PE-Cy7 antibodies for 20 min at RT, followed by fixation and permeabilization using the eBioscience Intracellular Fixation and Permeabilization Buffer for 45 min at RT. Next, the cells were fixed with anti-human Ki67-PE and anti-human T-bet-APC antibodies (Biolegend) for 1 h at RT. The stained cells were analyzed using a BD FACSymphony A3 cytometer (BD, Franklin Lakes, NJ), and the data were analyzed by FlowJo (Tree Star, Ashland, OR). Unstained cells and cells stained with isotypes and single antibody were used as controls to determine staining background levels and to adjust for multicolor compensation as a gating strategy.

2.8. Statistical analysis

Data were analyzed using Prism 7 software (Irvine, CA) and are presented as mean ± SD or SEM. Comparisons between two groups were made using a parametric paired or unpaired t-test (with or without Welch’s correction for unequal or equal SD, respectively) for normally distributed data or non-parametric Wilcoxon paired t-test or Mann-Whitney U-test for non-normal distributions. Comparisons among multiple groups were made using one-way ANOVA at a 95% confidence level (Tukey’s honest significance test). The magnitude of correlation was analyzed with Pearson correlation coefficient (parametric approach) or nonparametric Spearman correlation. P-values < 0.05 (*) were considered statistically significant, and p-values < 0.01 (**) < 0.001 (***) or < 0.0001 (****) were considered very significant.

3. Results

3.1. Identification of potential B-cell epitopes on the SARS-CoV-2 proteome

The pan-coronavirus microarrays are specifically designed to screen for linear epitopes by measuring plasma antibody reactivity against coronaviral peptides. These microarrays contain 5513 peptides stemming from different HCoV proteins, including 3546 peptides for SARS-CoV-2, 484 peptides for SARS-CoV-1, 506 peptides for MERS, and 457 or 520 peptides for the common colds HCoV 229E or OC43, respectively. As shown in Fig. 1A, each peptide microarray comprises three identical subarrays, and each spot in the microarray represents a single individual peptide. To identify SARS-CoV-2-specific B-cell epitopes, we used convalescent plasma from COVID-19-recovered patients (n = 6) versus HS control (n = 1). After incubating the unheated plasma with the peptide arrays, the antibodies bound with peptides were detected using fluorescently labeled secondary antibodies. As shown in Fig. 1B, among the 5513 peptides stemming from different HCoV proteomes, 13 peptides were identified as strongly reactive (> 2-fold) to the plasma IgG antibodies in at least 3 out of 6 COVID-19-recovered patients compared with the HS control. These 13 peptides were all from the SARS-CoV-2 proteome, including 3 spike protein peptides (S 557–571, S 789–803, and S 809–823), 1 membrane protein peptide (M 5–19), 3 nucleoprotein peptides (N 161–175, N 233–247, and N 397–411), and 6 replicase polyprotein 1 peptides (R1a 649–663, R1b 537–587, R1b 909–923, R1ab 2349–2363, R1ab 3853–3867, and R1ab 4187–4175). These virus-specific peptides, recognized by antibodies in the COVID-19 convalescent plasma, represent potential B-cell epitopes in the SARS-CoV-2 proteome that warrant further validation and characterization.

3.2. Validation of SARS-CoV-2-specific B-cell epitopes

To validate these potential B-cell epitopes on SARS-CoV-2, we synthesized these 13 peptides (by GeneScript) and assessed their reactivity to both COVID-19 convalescent plasma (n = 66) and control plasma (n = 26) using peptide-based ELISA. As shown in Fig. 2A, the peptides S 809–823, M 5–19, and R1ab 909–923 strongly reacted with convalescent plasma from COVID-19 patients compared with those from controls. We have recently reported that SARS-CoV-2 antibodies decline rapidly in the plasma of COVID-19-recovered patients, with IgG titers decreasing to non-significant levels after 3 months post-infection (Wang et al., 2021) To determine the durability of these antibodies against our identified epitopes, we divided the patient cohort into several subgroups (i.e., <20 days, ≤60 days, < 90 days, and > 90 days) based on the time of plasma collection after COVID-19 symptom onset. Interestingly, peptides S 809–823 (Fig. 2D) and R1ab 909–923 (Fig. 2G) significantly reacted with convalescent plasma collected at < 20, ≤60, and < 90 days after COVID-19 symptom onset, but not with the plasma collected > 90 days after COVID-19 symptom onset. Peptide M 5–19 (Fig. 2E) strongly reacted with convalescent plasma collected at > 90 days of COVID-19 symptom onset, but not with plasma from the other subgroups. We did not observe any significant differences in reactivity of peptide S 557–571 (Fig. 2B), S 789–803 (Fig. 2C), and N 161–175 (Fig. 2F) with convalescent plasma from all subgroups of COVID-19-recovered subjects. These results confirmed our peptide microarray data, validating the reactivity of SARS-CoV-2-specific B-cell immunodominant epitopes and the durability of their specific antibodies in the convalescent plasma of COVID-19 patients.
3.3. Correlation between SARS-CoV-2 peptide-specific antibody titers and neutralization rates

nAbs against SARS-CoV-2 block the interaction between the receptor-binding domain (RBD) of the S protein and the angiotensin-converting enzyme-2 (ACE2) cell surface receptor. To determine the presence of protective nAbs recognized by S1-RBD, 1:10 diluted COVID-19 convalescent plasma was incubated with HRP-conjugated, recombinant SARS-CoV-2-S1 RBD for 30 min at 37 °C before being added to an ACE2 pre-coated ELISA plates. The neutralization rates for blocking SARS-CoV-2 S RBD interaction with the ACE2 receptor were calculated as described in the Materials and Methods. The correlations between the neutralization rates and antibody titers measured by the peptide-based ELISA were analyzed with the Pearson correlation coefficient or nonparametric Spearman correlation, depending on if the data followed a normal distribution. As shown in Fig. 3A-B, E-F, and I-J, there were no correlations between the neutralization rates and antibody titers measured by peptide-based ELISA using the three S peptides (S 557–571, S 789–803, and S 809–823) as coating antigens and plasma from both < 60 days and > 90 days subgroups. Given the rapid decline of the SARS-CoV-2 antibody titers in COVID-19 convalescent plasma, we further analyzed the antibody titers and neutralization rates in samples collected from the < 60 days and < 20 days subgroups. The neutralization rates positively correlated with the S 789–803-reactive antibodies in the plasma collected at < 20 days (p = 0.0371, r = 0.7113) and < 60 days (p = 0.0225, r = 0.3772) (Fig. 3G-H), suggesting that S 789–803 peptide is a neutralizing epitope. Taken together, these data suggest that the levels of antibodies in COVID-19 convalescent plasma that target the S 789–803 peptide positively correlate with their neutralizing activities at the early phase of COVID-19 recovery, however, the titers of these SARS-CoV-2 B-cell epitope-reactive antibodies diminish quickly, with no correlation to the nAb activity beyond 2 months of recovery.

3.4. Characterization of SARS-CoV-2 neutralizing epitopes

A pseudotyped lentivirus system expressing SARS-CoV-2 S glycoprotein tagged with green fluorescent protein (GFP) and a luciferase reporter allow rapid and safe assessment of nAbs in convalescent plasma of COVID-19 patients (Wang et al., 2021; Schmidt et al., 2020). To further assess if the antibodies against SARS-CoV-2 S epitopes could interfere with the interaction between SARS-CoV-2 S RBD and host cell ACE2 receptor, we performed a modified neutralization assay using Ab-depleted plasma and the identified S peptides and compared it with the corresponding non-depleted plasma that has relatively high titers of virus-specific antibodies as blocking agents. The Ab depletion was carried out by incubating the plasma with SARS-CoV-2 S protein or B-cell epitope-coated plates for 24 rounds, as described in the Materials and Methods. Depletion efficiency was validated by peptide-based ELISA, and the results showed that the levels of the antibodies targeting S protein, S peptides or M peptide were significantly and dramatically diminished compared with non-depleted controls (Fig. 4A). The non-depleted and Ab-depleted plasma from COVID-19-recovered patients were then incubated with the SARS-CoV-2–S A19 pseudotyped luciferase-EGFP lentivirus for 1 h at 37 °C, followed by infection of 293 T/ACE2 cells for 3 days as we reported previously (Wang et al.,
The fluorescent images were captured before measuring luciferase activities, and the representative images are shown in Fig. 4B. Compared with the cells treated with the non-depleted or BSA-depleted patient plasma, we observed significantly more EGFP (green) positive cells in the infected 293 T cells treated with S 557–571-, S 789–803-, or S 809–823-depleted plasma — similar to those treated with S protein-depleted plasma. There was no much difference on EGFP green cells between the infected 293T cells treated with M5–19-depleted and BSA-depleted plasma. These data indicated that the inhibition of the interaction between S protein on the pseudovirus and ACE2 on 293T cells was attenuated due to the depletion of nAbs in COVID-19 convalescent plasma by these three S peptides (i.e., neutralization epitopes), resulting in an increased pseudovirus infection. Consistent with the EGFP images, data from the luciferase assay (Fig. 4C) showed that the nAbs of COVID-19 convalescent plasma were significantly suppressed by the depletion of antibodies that target the S protein and these three S peptides, but not M5–19, compared with the control (BSA)-depleted plasma. Taken together, these results demonstrate that the specific antibodies targeting the S 557–571, S 789–803, and S 809–823 peptides play an important role in neutralizing SARS-CoV-2 infection and that these virus-specific peptides represent SARS-CoV-2 neutralizing epitopes capable of eliciting B-cell nAb responses.

3.5. B cell activation in response to identified B-cell epitopes of SARS-CoV-2

To measure B-cell responses to virus-specific and non-specific stimulations, we cultured PBMCs from COVID-19-recovered patients and HS in the presence or absence of SARS-CoV-2 S protein, mixed S peptides (S 557–571, S 789–803 and S 809–823), or the rhIL-2 + R848 for 24 h, followed by flow cytometry analysis to determine the levels of B-cell activation, proliferation, and differentiation markers.

CD86, CD25 and CD30 are transmembrane glycoproteins expressed in activated B cells. CD86 is rapidly upregulated on B cells following activation by the cross-linking of the Ig receptor or a variety of cytokines (Lenschow et al., 1993). B cells expressing CD25 display a mature and activated phenotype belonging to the memory B-cell subset and have a more robust proliferative and antigen-presenting capacity (Amu and Brisslert, 2011). CD30 has been recognized as a unique marker in many lymphomas and as an activation molecule on B cells (Muta and Podack, 2013). We first measured the expression of CD86 on CD19+ cells in PBMCs of COVID-19-recovered patients. As shown in Fig. 5A, while COVID-19 patients’ B cells responded to the rhIL-2 and R848 non-specific stimulation as robustly as those of HS, they didn’t exhibit any increase in CD86 expression in response to SARS-CoV-2 S protein compared with B cells from HS or unstimulated B cells. The expression of CD25 and CD30 was extremely low, with no significant differences amongst all groups (data not shown).

PDL-1 is the ligand for the PD-1 inhibitory receptor and serves as an activation marker on antigen-presenting cells, including B-cells. Similar to CD86 expression, we found that PDL-1 level was remarkably and equally upregulated by the non-specific stimulation (rhIL-2+R848) of B cells from both HS and COVID-19-recovered patients, indicating their potent responsiveness. However, while PDL-1 expression was significantly upregulated in COVID-19 patients’ B cells stimulated with SARS-CoV-2 S protein compared with HS or unstimulated B cells, this antigen-specific upregulation was not observed in B cells stimulated by the mixed S peptides (Fig. 5B).

To determine memory B cell differentiation and function in response
to this antigenic stimulation, we treated PBMCs as described above and stained them with anti-human CD19, CD20, CD38, CD21, CD27, and Ki67, IgG, or IgM antibodies for flow cytometry analysis. The gating strategy for naïve (CD19⁺CD20⁺CD38⁻CD21⁺CD27⁻) and memory B cells (CD19⁺CD20⁺CD38⁻CD21⁻CD27⁻ /CD21⁻CD27⁺ /CD21⁻CD27⁺) are shown in Fig. 5 C. While the overall frequencies of memory B cells were slightly higher in COVID-19-recovered patients compared with HS, we did not observe increases in the memory B cells stimulated with SARS-CoV-2 S protein or mixed S peptides (data not shown). Similar to the pattern of PDL-1 expression, IgG production by memory B cells was significantly upregulated when PBMCs from COVID-19 patients were stimulated with SARC-CoV-2 S protein but not S peptides when compared with unstimulated control or HS (Fig. 5 D). There were no significant differences in IgM⁺ memory B cell numbers amongst all groups when PBMCs were subjected to virus-specific stimulation (data not shown). Also, there was no significant difference in Ki67 (a proliferation marker) expression in memory B cells amongst all groups following virus-specific stimulation of PBMCs, although the Ki67 level was remarkably and equally upregulated in memory B cells in response to rhIL-2/R848 stimulation (data not shown).

Previous studies showed that antigen-specific memory B cells expressing transcription factor T-bet persisted in circulation over time after primary infection or vaccination, and their number correlates with long-lived antibody responses. T-bet⁺ memory B cells reactivated by re-infection rapidly proliferate and then differentiate into protective plasmablasts to produce high-affinity and viral-specific IgG antibodies (Nellore et al., 2019; Knox et al., 2019, 2017). We thus measured T-bet expression in memory B cells within PBMCs in response to virus-specific stimulation. As shown in Fig. 5E, there was no significant difference in T-bet expression in memory B cells within PBMCs from COVID-19-recovered patients compared with HS.

Taken together, these results suggest that virus-specific B-cell activation in response to the identified SARS-CoV-2-specific epitopes is attenuated in COVID-19-recovered patients, albeit T-bet expression remains responsive to virus-specific stimulation.

4. Discussion

In this study, we identified virus-specific B-cell epitopes of the SARS-CoV-2 proteome and characterized both the durability of their neutralizing antibodies in convalescent plasma and the function of memory B cells from COVID-19-recovered patients. We demonstrated that while these SARS-CoV-2 B-cell epitopes can elicit virus-specific antibodies, these antibodies are not durable in the convalescent plasma and lose their neutralizing activities within a few months after recovery from COVID-19 disease. In addition, we found that B-cell activation in response to the identified virus-specific epitopes is attenuated in COVID-19-recovered patients. These findings potentially support the notion that COVID-19-recovered individuals might require booster dosing of the COVID-19 vaccine to extend protection from severe disease and detrimental outcomes.

The PepStar Peptide Microarrays (by JPT Peptide technologies) are an attractive tool for identifying potential biomarkers for infectious diseases, autoimmune diseases, cancer, and allergies, and for uncovering protein-protein interactions. Because of the high cost of the Peptide Microarrays, only 6 COVID-19 patient plasma samples were used for initial microarray screen. To avoid data bias due to the small number of patients, the selected patients had high diversities on their ages, genders, IgG antibody titers, and neutralization rates (Supplemental Table 1). Using this powerful microarray, we identified the B-cell epitopes on SARS-CoV-2 and then validated their reactivity by peptide-based ELISA using convalescent plasma from COVID-19-recovered patients. Notably, the antibody titers measured by the peptide-based ELISA positively correlated with the antibody neutralizing rates in a time-dependent
Fig. 4. Identification of neutralizing epitopes using Ab-depletion and neutralization assays. A) Ab-depletion efficiency validated by the peptide-based ELISA. Values were normalized to the non-depleted control. The data are summarized using 4 plasma samples from COVID-19-recovered patients. *P < 0.05; **P < 0.01; ***P < 0.001; **P < 0.0001; NS = not significance, as determined by paired t-test, and mean ± SD. B) Representative fluorescent images for neutralization assays using SARS-CoV-2 ΔS19 pseudotyped luciferase-EGFP lentivirus infection of 293 T/ACE2 cells in the presence of blocking plasma depleted with the indicated peptides. The percentage (%) of neutralization by plasma antibodies depleted of the respective peptides. Values were normalized to the BSA control. The data are summarized from the antibody-depletion assays using 12 (S 557–571, S789–803, and M 5-19) or 15 (S protein and S 809–823) plasma samples from COVID-19-recovered patients. *P < 0.05; **P < 0.01; NS = not significance, as determined by paired t-test, and mean ± SD. C) The percentage (%) of neutralization by plasma antibodies depleted of the respective peptides. Values were normalized to the BSA control. The data are summarized from the antibody-depletion assays using 12 (S 557–571, S789–803, and M 5-19) or 15 (S protein and S 809–823) plasma samples from COVID-19-recovered patients. *P < 0.05; **P < 0.01; NS = not significance, as determined by paired t-test, and mean ± SD.

We determined the function of these immunodominant epitopes using a lentivirus system expressing SARS-CoV-2 S glycoprotein that allows for the rapid and safe assessment of nAbs in convalescent plasma of COVID-19 patients in a BSL-2 laboratory. Functionally, antibody depletion with the identified S peptides (S557–571, S789–803, and S809–823) showed that antibodies targeting these three epitopes significantly altered viral neutralization capacity, suggesting that these epitopes are indeed neutralizing sites on the S protein of SARS-CoV-2. Notably, the S557–571 epitope is located on the S1 subunit of the S protein proximal to the RBD. It is highly likely that the antibodies that target this site interfere with SARS-CoV-2 S glycoprotein binding to the ACE2 receptor, thereby abolishing virus entry and infection. The other two epitopes identified in this study (S789–803 and S809–823) are localized on the S2 subunit and cover part of the fusion domain, which is relatively conservative amongst HCoVs (Bangaru et al., 2020). Previous studies showed targeting the SARS-CoV, SARS-CoV-2, and MERS-CoV fusion domain suppressed HCoV infection with a pan-HCoV peptide inhibitor (Xia et al., 2019, 2021). Importantly, our peptides S557–571 and S809–823 overlap with the S14P5 and S21P2 peptides that were previously described (Poh et al., 2020; Amrun et al., 2020). These two independent studies showed consistent and significant recognition of S809–823 by plasma from recovered SARS-CoV-2 patients, which further support our findings.

The expression of T-bet - a reliable marker of memory B cell antiviral function - is increased during SARS-CoV-2 infection, especially in symptomatic patients (Notarbartolo et al., 2021; Reyes et al., 2021; Rodda et al., 2021), and is maintained at high levels for a few months after disease onset (Rodda et al., 2021). At this point, the frequency of virus-specific T-bet+ IgG+ memory B cells decreases to a baseline level (Reyes et al., 2021). Our data further demonstrated that T-bet+ memory B cells rapidly declined in COVID-19 patients after 3 months of recovery. Significantly, we found that their levels can be upregulated upon re-exposure to SARS-CoV-2 S protein or S peptides, suggesting that protective immune responses could be re-induced in these recovered patients.

Remarkably, we didn’t detect a robust or universal B-cell response (other than T-bet expression) in PBMCs from COVID-19-recovered patients following stimulation with a mixture of these linear neutralizing peptides, despite memory B cell response to the S protein or non-specific stimulation. It is likely that these B-cell epitopes only represent a portion of the total anti-S antibody response (Lv et al., 2020; Wu et al., 2020). It is also possible that these synthetic linear B-cell peptides lack the structural conformation and post-translational modifications of the whole S glycoprotein, which are essential for efficient antigenic stimulation. Future studies are needed to fully understand the role and neutralization capacity of antibodies targeting these epitopes and the durability of memory B cells in the blood of COVID-19-recovered patients. Nevertheless, our studies provide a guide for the design and evaluation of sensitive and specific serology tests against these virus-specific B-cell epitopes and may help in prioritizing and improving vaccine and therapeutic targets against this devastating infectious disease.

CRediT authorship contribution statement

Ling Wang: Conceptualization, Methodology, Validation, Formal analysis, Investigation, Data Curation, Writing – original draft, Writing – review & editing. Juan Zhao: Investigation, Writing – review & editing. Madison Schank: Investigation, Writing – review & editing. Sushant Khanal: Investigation. Xindi Dang: Investigation. Dechao Cao: Investigation.
Investigation. Lam N.T. Nguyen: Investigation. Yi Zhang: Investigation. Xiao Y. Wu: Project administration. James L. Adkins: Resources. Justin Brueggeman: Investigation. Jinyu Zhang: Writing – review & editing. Shunbin Ning: Writing – review & editing. Mohamed El Gazzar: Writing – review & editing. Jonathan P. Moorman: Writing – review & editing, Funding acquisition. Zhi Q. Yao: Conceptualization, Writing – review & editing, Supervision, Funding acquisition.

Competing interests

The authors declare no competing financial interests.

Data availability

Data will be made available on request.

Acknowledgments

This work was supported by National Institutes of Health (NIH) grants R21AI157909 and R15AG069544; Veteran Affairs (VA) Merit Review Awards 1101BX002670 and 1101BX004281; ADA award 7–20-COVID-149; and DoD Award PR170067 (to Z.Q.Y); and VA award 5I01BX005428 (to J.P.M). This publication is the result of work supported with resources and the use of facilities at the James H. Quillen Veterans Affairs Medical Center. The contents in this publication do not represent the views of the Department of Veterans Affairs or the United States Government.

Author Contributions

L.W. performed most of the experiments, J.Z., M.S., K.D., D.C., L.N.T.N., Y.Z., J.L.A and J.B. performed some experiments. J.P.M. coordinated human subject recruitment. X.Y.W provided technical support. M.E., J.Y.Z. S.N., and J.P.M. provided intellectual input for troubleshooting and discussed the results. Z.Q.Y. supervised the research and wrote the manuscript, with the help of all co-authors.

Appendix A. Supporting information

Supplementary data associated with this article can be found in the online version at doi:10.1016/j.molimm.2022.10.016.

References

Ahmed, S.F., Quadeer, A.A., McKay, M.R., 2020. Preliminary identification of potential vaccine targets for the COVID-19 coronavirus (SARS-CoV-2) based on SARS-CoV immunological studies. Viruses 12, 3.
Amrun, S.N., et al., 2020. Linear B-cell epitopes in the spike and nucleocapsid proteins as markers of SARS-CoV-2 infection. EBioMedicine 58, 102911.
Amu, S., Brisslert, M., 2011. Phenotype and function of CD25-expressing B lymphocytes isolated from human umbilical cord blood. Clin. Dev. Immunol. 2011, 481948.
Bacchis, S., et al., 2020. Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate. Science 370 (6520), 1089–1094.
Crotty, S., et al., 2003. Cutting edge: long-term B cell memory in humans after smallpox vaccination. J. Immunol. 171 (10), 4969–4973.
Grifoni, A., et al., 2020. A sequence homology and bioinformatic approach can predict candidate targets for immune responses to SARS-CoV-2. Cell Host Microbe 27 (4), 671–680 e2.
Jeneiway, C.A., Jr, T.P., Walport, M., et al., 2001. Immunobiology: The Immune System in Health and Disease, fifth ed. Garland Science, New York.
Johnson, N.P., Mueller, J., 2002. Updating the accounts: global mortality of the 1918-1920 'Spanish' influenza pandemic. Bull. Hist. Med. 76 (1), 105–115.

Knox, J.J., Kaplan, D.E., Betts, M.R., 2017. T-bet-expressing B cells during HIV and HCV infections. Cell Immunol. 321, 26–34.

Knox, J.J., Myles, A., Cancro, M.P., 2019. T-bet(+) memory B cells: generation, function, and fate. Immunol. Rev. 288 (1), 149–160.

Lenschow, D.J., et al., 1993. Expression and functional significance of an additional ligand for CTLA-4. Proc. Natl. Acad. Sci. USA 90 (23), 11054–11058.

Lv, H., et al., 2020. Cross-reactive antibody response between SARS-CoV-2 and SARS-CoV infections. Cell Rep. 31 (9), 107725.

Muta, H., Podack, E.R., 2013. CD30: from basic research to cancer therapy. Immunol. Res 57 (1–3), 151–158.

Nellore, A., et al., 2019. Fcrl5 and T-bet define influenza-specific memory B cells that predict long-lived antibody responses. bioRxiv: p. 643973.

Notarbartolo, S., et al., 2021. Integrated longitudinal immunophenotypic, transcriptional and repertoire analyses delineate immune responses in COVID-19 patients. Sci. Immunol. 6, 62.

Organization, W.H., Coronavirus disease (COVID-2019) situation reports. 2021.

Poh, C.M., et al., 2020. Two linear epitopes on the SARS-CoV-2 spike protein that elicit neutralizing antibodies in COVID-19 patients. Nat. Commun. 11 (1), 2806.

Reyes, R.A., et al., 2021. SARS-CoV-2 spike-specific memory B cells express markers of durable immunity after non-severe COVID-19 but not after severe disease. bioRxiv.

Rodda, L.B., et al., 2021. Functional SARS-CoV-2-specific immune memory persists after mild COVID-19. Cell 184 (1), 169–183.

Schmidt, F., et al., 2020. Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses. J. Exp. Med. 217, 11.

Seifert, M., Küppers, R., 2016. Human memory B cells. Leukemia 30 (12), 2283–2292.

Wang, H., et al., 2020. SARS-CoV-2 proteome microarray for mapping COVID-19 antibody interactions at amino acid resolution. ACS Cent. Sci. 6 (12), 2238–2249.

Wang, L., et al., 2021. Blockade of SARS-CoV-2 spike protein-mediated cell-cell fusion using COVID-19 convalescent plasma. Sci. Rep. 11 (1), 5558.

Weisel, F., Shlomchik, M., 2017. Memory B cells of mice and humans. Annu Rev. Immunol. 35, 255–284.

Wu, F., et al., 2020. Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications. medRxiv: p. 2020.03.30.20047365.

Xia, S., et al., 2019. A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike. Sci. Adv. 5 (4), eaav4580.

Xia, S., et al., 2021. Structural and functional basis for pan-CoV fusion inhibitors against SARS-CoV-2 and its variants with preclinical evaluation. Signal Transduct. Target Ther. 6 (1), 288.

Zhao, J., et al., 2021. SARS-CoV-2 specific memory T cell epitopes identified in COVID-19 recovered subjects. Virus Res. 304, 198508.

Zheng, M., Song, L., 2020. Novel antibody epitopes dominate the antigenicity of spike glycoprotein in SARS-CoV-2 compared to SARS-CoV. Cell Mol. Immunol. 17 (5), 536–538.